Related by context. All words. (Click for frequent words.) 79 placebo controlled Phase 76 dose escalation trial 76 phase Ib 76 Phase 2a trial 75 Phase 1b clinical 75 multicenter Phase II 75 Phase 2a clinical 75 phase IIb 75 Phase Ib clinical 75 phase IIa clinical 75 Phase 1b 74 Phase Ib 74 dose dose escalation 74 phase IIa 73 Phase Ib II 73 Phase Ib study 73 phase IIb clinical 73 multicenter Phase 73 phase 2a 73 Phase #b/#a 72 confirmatory Phase III 72 Phase 2a 72 Phase 1b trial 72 Phase 1a 72 Phase 2b trial 72 multicenter phase 72 Phase Ia 72 Phase 2b study 72 randomized multicenter 71 Phase IIa trial 71 Initiated Phase 71 dose escalation clinical 71 randomized controlled Phase 71 Phase 1a clinical 71 PRECiSE 71 placebo controlled Phase III 71 Phase #/#a 70 multicenter randomized placebo controlled 70 Phase IIIb 70 dose escalation study 70 BRIM2 70 Phase IIa 70 randomized Phase IIb 70 double blinded placebo 70 phase IIb study 70 placebo controlled clinical 70 Phase IIa clinical 70 LUX Lung 70 Phase IIIb clinical 70 placebo controlled randomized 70 Phase 2b 70 multicenter randomized 70 phase IIIb 70 multicentre randomized 70 multiple ascending dose 69 single ascending dose 69 dosing cohort 69 randomized multicentre 69 Phase IIa trials 69 controlled multicenter 69 randomized Phase III 69 randomized Phase 69 ongoing Phase 1b 69 Phase #b/#a trial 69 HCV SPRINT 69 Aplidin 69 prospective multicenter 69 Phase IIb trial 69 rALLy clinical trial 69 pivotal bioequivalence 69 randomized Phase 2b 69 multicenter randomized Phase 69 controlled multicenter Phase 69 multicenter placebo controlled 69 IIa trial 69 BRIM3 69 Phase #b/#a clinical 69 Amrubicin 68 Phase IIB 68 label dose escalation 68 confirmatory Phase 68 ascending dose 68 sunitinib malate 68 Phase IIb trials 68 AEG# 68 ADVANCE PD 68 ganetespib 68 phase IIb trial 68 Phase III randomized 68 NO# [002] 68 double blinded randomized 68 Phase IIb clinical 68 dose escalation 68 phase Ib clinical 68 blinded randomized placebo controlled 68 prospective randomized multicenter 68 alvespimycin 68 pharmacokinetic PK study 68 nonrandomized 68 registrational trial 68 Phase III 68 teriflunomide 68 Phase 2a clinical trials 68 registrational 68 multicenter clinical 68 oral ridaforolimus 68 HGS# 68 treatment naive genotype 68 viral kinetic 68 Phase IIb clinical trials 67 R#/MEM # 67 Phase III randomized controlled 67 GALNS 67 label multicenter randomized 67 receptor tyrosine kinase inhibitor 67 Phase 2b clinical 67 Phase III pivotal 67 PSN# [002] 67 Cloretazine ® 67 Phase III clinical 67 Phase 1b clinical trials 67 pivotal Phase 67 label multicenter Phase 67 IMA# 67 GLP toxicology studies 67 TMC# C# 67 pharmacokinetic PK 67 trastuzumab emtansine T DM1 67 axitinib 67 dose cohort 67 treatment naïve genotype 67 initiate Phase 1b 67 Phase 2b randomized 67 pivotal Phase III 67 label multicenter 67 Randomized Phase 67 deforolimus 67 fosbretabulin 67 pharmacokinetics PK 67 elotuzumab 67 Phase III placebo controlled 67 Carfilzomib 66 dose cohorts 66 Phase 66 MEND CABG II 66 Phase III Pivotal 66 ruxolitinib 66 JAK inhibitor 66 HuMax EGFr 66 placebo controlled 66 Phase IIb 66 multicenter randomized controlled 66 BR.# 66 Initiate Phase 66 EOquin TM 66 multicenter Phase III 66 PRIMO CABG 66 SUCCEED trial 66 multicenter prospective 66 relapsed refractory multiple myeloma 66 IIa trials 66 Tyrima 66 Phase lll 66 multicentre 66 active comparator 66 Phase 2b clinical trials 66 enzastaurin 66 APEX PD 66 PRE SURGE 66 Phase IIA 66 INCB# [001] 66 sorafenib Nexavar ® 66 Phase IIb III 66 ascending doses 66 Azedra 66 TG MV 66 dosing cohorts 66 Phase III confirmatory 66 depsipeptide 66 masked placebo controlled 66 initiated Phase Ib 66 budesonide foam 66 ABSORB trial 66 RSD# oral 66 HCV RESPOND 2 66 hematological tumors 66 docetaxel Taxotere R 66 MEND CABG 66 HCD# [002] 66 GetGoal Phase III 66 multicentre randomized double 66 PEG PAL 65 Alzhemed TM 65 YONDELIS 65 PDE4 inhibitor 65 prospective randomized placebo 65 CR# vcMMAE 65 elacytarabine 65 AQ4N 65 pomalidomide 65 PXD# 65 mertansine 65 metastatic HRPC 65 riociguat 65 forodesine 65 IMC A# 65 IIa clinical 65 Traficet EN 65 Phase 2b monotherapy 65 ATL# [001] 65 SCCHN 65 OvaRex ® MAb 65 ELACYT 65 PFO migraine 65 PF # [001] 65 Alocrest 65 ToGA 65 prospective randomized controlled 65 HGS ETR2 65 CRLX# 65 TEMSO 65 preclinical efficacy 65 GOUT 65 huC# DM4 65 Atu# 65 HGS ETR1 65 Plicera 65 Sym# 65 Xanafide 65 BAY #-# 65 multicenter randomized double 65 Phase III multicenter 65 cediranib 65 AIR CF3 65 RE LY 65 blind randomized placebo 65 REVIVE Diabetes 65 Phase II 65 phase IIb III 65 ENDEAVOR IV 65 ZYBRESTAT fosbretabulin 65 midstage trials 65 PDX pralatrexate 65 Pivotal Phase 65 efficacy endpoint 64 PRESEPT 64 NP2 Enkephalin 64 AP# [003] 64 cannabinor 64 Dose escalation 64 trastuzumab DM1 T DM1 64 pertuzumab 64 Annamycin 64 tolevamer 64 TELCYTA 64 MERLIN TIMI 64 randomized blinded 64 pharmacodynamic profile 64 crizotinib PF # 64 confirmatory clinical 64 PSMA ADC 64 orally bioavailable 64 Omacetaxine 64 bendamustine 64 Panzem R NCD 64 liposomal formulation 64 TMC# [002] 64 NOX E# 64 brivaracetam 64 randomized placebo controlled 64 randomized controlled 64 galiximab 64 evaluating Xcytrin 64 assessing T DM1 64 Phase Ib clinical trials 64 relapsed MM 64 Sorafenib HCC Assessment 64 pharmacokinetic studies 64 lorcaserin Phase 64 rALLy 64 CHAMPION PCI 64 ANCHOR trial 64 obatoclax 64 Quinamed 64 oral prodrug 64 fidaxomicin Phase 3 64 Cloretazine R VNP#M 64 prospective multicenter randomized 64 EDEMA3 64 Tarceva TM 64 sorafenib Nexavar 64 TASKi2 64 unblinded 64 tramiprosate Alzhemed TM 64 IL# PE#QQR 64 trodusquemine 64 blinded randomized 64 Dacogen injection 64 anti leukemic 64 Phase IIIb study 64 unblinding 64 novel histone deacetylase 64 solithromycin 64 ularitide 64 COMFORT II 64 HER2 positive metastatic breast 64 MEK inhibitor 64 sequential dose escalation 64 VNP#M 64 Phenoptin 64 Cloretazine 64 DermaVir Patch 64 blind randomized 64 MGd 64 Bezielle 64 HuMax CD4 64 tesmilifene 64 trial evaluating PRX# 64 blind multicenter 64 adecatumumab 64 evaluating tivozanib 64 ofatumumab HuMax CD# 64 acyclovir Lauriad R 64 LUMINATE 64 CLORETAZINE TM VNP#M 63 afatinib 63 lomitapide 63 bardoxolone 63 TACI Ig 63 TRO# 63 EGS# 63 lintuzumab 63 RezularTM 63 EndoTAG 63 Zemplar Capsules 63 CA4P 63 OMP #M# 63 TBC# 63 Phase III metastatic melanoma 63 blind randomized controlled 63 velafermin 63 BRAF inhibitor 63 Genz # 63 multicenter 63 RRMS patients 63 PRT# 63 GV# [001] 63 prucalopride 63 midstage clinical 63 AeroLEF TM 63 Urocidin 63 OHR/AVR# 63 romidepsin 63 IMC #B 63 randomized controlled multicenter 63 tanespimycin 63 prospective observational 63 prospective randomized 63 Phase 2b kidney transplant 63 oral deforolimus 63 Sapacitabine 63 amrubicin 63 MAGE A3 ASCI 63 OncoVEX GM CSF 63 brentuximab vedotin SGN 63 APPRAISE 63 cathepsin K inhibitor 63 multicenter randomized clinical 63 Onrigin 63 Mipomersen 63 randomized multicenter trial 63 placebo controlled multicenter 63 fostamatinib 63 PANVAC VF 63 Velcade bortezomib 63 placebo controlled dose escalation 63 blinded placebo controlled 63 Ophena TM 63 huN# DM1 63 Phase 1b dose escalation 63 placebo controlled studies 63 selective androgen receptor modulator 63 label dose titration 63 oral rivaroxaban 63 GRN# 63 randomized controlled clinical 63 ILLUMINATE 63 Deforolimus 63 iniparib 63 SPIRIT FIRST 63 Phase IIa proof 63 Aflibercept 63 Fx #A 63 MEK inhibitor RDEA# 63 Pivotal Phase III 63 CIMZIA ™ 63 AIR CF1 63 CEQ# 63 RhuDex ® 63 lead Aganocide compound 63 EndoTAG TM -1 63 entinostat 63 eniluracil 63 clinical trial 63 XmAb# 63 ORMD 63 AVADO 63 StemEx 63 European Sepsis Trial 63 thorough QT 63 ACCLAIM COPD 63 anticancer compound 63 neratinib 63 Zenvia ™ 63 vidofludimus 63 Telatinib 63 TRISENOX 63 celgosivir 63 PROSTVAC TM 63 oncolytic vaccine 63 APTIVUS 63 radiation sensitizer 63 maximally tolerated dose 63 refractory metastatic colorectal cancer 63 CCX# 63 farletuzumab 63 Tesetaxel 63 ALN VSP Phase 63 Maximum Tolerated Dose MTD 63 torezolid phosphate 63 ENMD # 63 subanalysis 63 eprotirome 63 Phase III trials 63 Troxatyl 63 metaglidasen 63 PEARL SC 63 ZACTIMA 63 satraplatin Phase 63 incyclinide 63 STRIDE PD 63 Targretin 63 AKT inhibitor 63 IMPACT DCM 63 Archexin 63 MGCD# [001] 62 GRNVAC1 62 BrachySil TM 62 PI3K/Akt pathway inhibitor 62 AEGR 62 multicenter multinational 62 Androxal TM 62 Akt inhibitor 62 Phase Ib IIa 62 Aryplase 62 HQK 62 Ereska 62 Cloretazine R 62 Ozarelix 62 indibulin 62 nab paclitaxel 62 OncoGel 62 AVOREN 62 hematological cancers 62 NEO3 62 PrevOnco 62 Phase #/#a trial 62 CAMMS# 62 antibody MAb 62 Allovectin 7 62 biliary tract cancer 62 dirucotide 62 PROSTVAC ® 62 COSIRA trial 62 ganaxolone 62 inhaled AAT 62 Ophena 62 Allovectin 7 ® 62 relapsed myeloma 62 GAMMAGARD 62 safety tolerability pharmacokinetic 62 glufosfamide 62 Solorel 62 CB2 selective receptor agonist 62 talabostat 62 PRX# 62 Dacogen decitabine 62 ARDIS 62 ChronVac C ® 62 sodium glucose cotransporter 62 BrachySil 62 Bayer HealthCare Onyx Pharmaceuticals 62 omacetaxine mepesuccinate 62 bavituximab monotherapy trial 62 Diamyd ® 62 pharmacodynamic effects 62 safety tolerability pharmacokinetics 62 mg/m2 cohort 62 ISIS # 62 randomized controlled clinical trials 62 OPT CHF 62 Pivotal Trial 62 bicifadine 62 dose escalation phase 62 Clolar ® 62 MDV# 62 BCIRG 62 XL# XL# XL# 62 cilengitide 62 CALGB 62 CIMZIA TM certolizumab pegol 62 prospective multicentre 62 PD LID 62 reslizumab 62 randomized clinical 62 SAR# [004] 62 Phase III psoriasis 62 HDACi 62 LibiGel Phase III 62 Myocet 62 KRAS mutations occur 62 delafloxacin 62 ZK EPO 62 GRN#L 62 RE SURGE 62 TLK# 62 EOquin 62 evaluating satraplatin 62 Dextofisopam 62 Tamibarotene 62 dacetuzumab 62 Panzem NCD 62 investigational humanized monoclonal antibody 62 evaluating mipomersen 62 pharmacodynamic PD 62 CLL8 62 Guanilib 62 Imprime PGG 62 JAK1 62 davunetide intranasal AL 62 bortezomib Velcade 62 telaprevir dosing 62 oral COTI 62 VITAL Trial 62 GSK# [001] 62 MIST II 62 ZYBRESTAT TM 62 KNS # 62 Aplidin R 62 Proxinium TM 62 PS# [001] 62 ospemifene 62 vascular disrupting agent 62 clinical pharmacology studies 62 otelixizumab 62 CoFactor 62 Aurora kinase inhibitor 62 CLARITY study 62 VICTOR E1 62 REG2 61 investigational protease inhibitor 61 AZX# Phase 61 aflibercept 61 rALLy trial 61 Gattex 61 Triapine 61 BLA submission 61 Perifosine 61 PRTX 61 orally administered inhibitor 61 thymalfasin 61 MabCampath 61 Spheramine 61 adecatumumab MT# 61 ofatumumab 61 unique alkylating agent 61 initiate Phase IIb 61 PS# DARA 61 ROCKET AF 61 LCP AtorFen 61 ABSORB clinical 61 ATL# [002] 61 placebo controlled trials 61 GEM OS2 61 urocortin 2 61 Cimzia ® certolizumab pegol 61 Spiegelmer ® 61 pharmacodynamics 61 ocular formulation 61 CLIRS 61 docetaxel chemotherapy 61 investigational pan BCR 61 LymphoStat B TM 61 nucleotide analog 61 JZP 61 cetuximab Erbitux R 61 Randomised 61 PHX# 61 eculizumab 61 FOLOTYN ® 61 evaluating Prochymal 61 inhibitor RG# 61 confirmatory Phase 3 61 CBLC# 61 Corlux 61 refractory CLL 61 bosutinib 61 OXi# 61 zalutumumab 61 ASA# 61 Augment Injectable 61 TAXUS IV 61 Phase III ALLEGRO 61 PF # [002] 61 subcutaneous methylnaltrexone 61 dexpramipexole 61 MAA submission 61 OncoVEX 61 papillary renal cell carcinoma 61 CIMZIA TM 61 PNP inhibitor 61 heavily pretreated 61 Elitek 61 Matrix Phase 2b 61 mGluR5 negative 61 histamine dihydrochloride 61 teduglutide 61 KSP inhibitor 61 CLL SLL 61 CALGB # [002] 61 TG# [003] 61 L BLP# 61 PEG SN# 61 RG# ITMN 61 initiate multicenter 61 LymphoStat B belimumab 61 Neuradiab 61 NLX P# 61 Zerenex 61 ascending dose study 61 trabectedin 61 Degarelix 61 perifosine KRX 61 Vectibix panitumumab 61 DDP# 61 tocilizumab 61 UPLYSO 61 tiuxetan 61 Kahalalide F 61 XL# SAR# 61 RSD# 61 metastatic hormone refractory 61 Phase #/#a clinical 61 ExTRACT TIMI 61 pain palliation 61 ORACLE MS 61 Vitaxin 61 preclinically 61 BETAS 61 VEGF Trap 61 cetrorelix 61 posaconazole 61 fidaxomicin Phase 61 PSN# [001] 61 DCCR 61 pitavastatin 61 Pralatrexate 61 ThermoDox R 61 Prostate AdenoCarcinoma Treatment 61 refractory AML 61 Phase III Clinical Trials 61 Study GL# 61 recurrent glioblastoma multiforme 61 methylnaltrexone 61 PEG IFN 61 blind placebo 61 NSABP B 61 immunotherapeutic agent 61 GED aPC 61 AIM HIGH 61 compound INCB# 61 myeloproliferative disorders 61 Proellex TM 61 lorvotuzumab mertansine 61 vemurafenib 61 including eniluracil ADH 61 cariprazine 61 glucokinase activator 61 HuMax CD# 61 Enzastaurin 61 evaluating T DM1 61 QLT# 61 IIa clinical trial 61 Blinatumomab 61 registrational Phase 61 MDS AML 61 Rezular 61 initiate Phase IIa 61 EVIZON 61 ancrod 61 desvenlafaxine succinate 61 TAXUS ATLAS 61 proteasome inhibitor 61 FOLFOX6 chemotherapy regimen 61 ACTEMRA TM 61 Vascular Wrap TM 61 Phase Ib IIa clinical 61 Glypromate 61 TAXUS V 61 JAK2 inhibitor 61 tolerated dose MTD 61 sulodexide 61 PREOS 61 prospectively defined 61 CLIRS trial 61 valopicitabine 61 Factor VIIa 61 IGF 1R inhibitor 61 pegylated liposomal doxorubicin 61 VADT 61 Safinamide 61 hA# 61 CUSTOM III 61 preclinical pharmacokinetic 61 isavuconazole 61 dextromethorphan quinidine 61 Benlysta belimumab 61 Capesaris 61 platinum refractory 61 YONDELIS R 61 generation FBPase inhibitor 61 Exherin TM 61 ChronVac C R 61 ASONEP 61 ARIKACE 61 dexanabinol 61 preclinical pharmacology 61 Pimavanserin 61 PIX# [002] 61 Phase III clinical trials 61 novel VDA molecule 61 Evoltra ® 60 eosinophilic asthma 60 generation purine nucleoside 60 Aclidinium 60 unblind 60 Squalamine 60 KRN# 60 DASISION 60 Tavocept 60 low dose cytarabine 60 CRMD# 60 palifosfamide Zymafos TM 60 Successfully Completes Phase 60 PRX # 60 DU #b 60 TASKi3 60 tolerability pharmacokinetics 60 trastuzumab DM1 60 MYDICAR 60 subgroup analyzes 60 Phase III ADT 60 platelet inhibitor 60 olaparib 60 TRC# 60 MYDICAR ® 60 HCV NS5B polymerase 60 Metastatic Melanoma 60 Xelox 60 pharmacokinetic pharmacodynamic 60 oral treprostinil 60 CAPACITY trials 60 evaluating carfilzomib 60 concurrent chemoradiation 60 TriRima 60 orally dosed 60 INCB# [003] 60 AZILECT R 60 sorafenib Nexavar R 60 randomized discontinuation trial 60 refractory CTCL 60 VEGF inhibitor 60 panitumumab 60 TOLAMBA 60 ACAPODENE 60 seliciclib CYC# 60 LBH# 60 Fibrillex TM 60 ONCONASE R 60 fistulizing Crohn disease 60 polycythemia vera essential thrombocythemia 60 generation antisense 60 secondary efficacy endpoints 60 NXL# 60 sitaxsentan 60 stated Michelle Berrey 60 ACCEDE 60 dose pharmacokinetic 60 HIV integrase inhibitor 60 NGX# 60 CYT# potent vascular disrupting 60 Folfox 60 Litx 60 ZD# [001] 60 double blind placebo 60 ocrelizumab 60 UVIDEM 60 TRANSFORMS 60 Phase IIa clinical trials 60 Novolimus 60 Glufosfamide 60 REOLYSIN ® 60 EDEMA4 60 PRIMO CABG2 60 Stimuvax R 60 GATTEX ® 60 RG# [001] 60 MLN# 60 ZOLINZA 60 rindopepimut 60 Randomized Phase II 60 plasma kallikrein inhibitor 60 TASQ 60 Ceflatonin R 60 Lu AA# 60 leading oral taxane 60 Epanova 60 hypoxia activated prodrug 60 RH1 60 Dyloject TM 60 initiate Phase 2b 60 Cannabinor 60 ENDEAVOR III 60 regorafenib 60 OMP #R# 60 EMPHASIS HF trial 60 octreotide implant 60 EndoTAGTM 1 60 Multiple Ascending Dose 60 Multicenter 60 lintuzumab SGN 60 IMGN# 60 Phase III VISTA 60 RE LY ® 60 Actilon 60 NSABP 60 IMPACT IMmunotherapy 60 Shigamabs ® 60 TOCOSOL Paclitaxel 60 PREOS R 60 Oral NKTR 60 systemic ALCL 60 dasatinib Sprycel 60 INCB# [002] 60 Tanespimycin 60 Zybrestat 60 PROSTVAC VF 60 placebo controlled clinical trials 60 ALN TTR# 60 SCH # 60 nalbuphine ER 60 Targretin capsules 60 evaluating Actimmune 60 volociximab 60 Seliciclib 60 PCI ExTRACT TIMI 60 cytokine refractory 60 pradefovir 60 recurrent glioblastoma 60 virus HCV protease inhibitor 60 generation proteasome inhibitor 60 seliciclib 60 budesonide MMX 60 MIVI TRUST 60 Exelixis compounds 60 GEM OS1 60 zanolimumab 60 multicenter trials 60 KB# [002] 60 stage IIIB 60 RGB # 60 randomized crossover 60 XIENCE V Stent System 60 GLPG# 60 Diamyd R 60 denufosol 60 generation Hsp# inhibitor 60 Feasibility Trial 60 Allovectin 7 R 60 NEVO RES 60 PRECISE 60 Hepatocellular Carcinoma HCC 60 AzaSite Plus 60 Vascugel ® 60 EXPLORE Xa 60 HuLuc# 60 sodium thiosulfate STS 60 AERAS-#/Crucell Ad# 60 torezolid 60 Symadex 60 ponatinib 60 vosaroxin 60 dextofisopam 60 mCRC patients 60 refractory chronic lymphocytic 60 CTAP# Capsules 60 NOD SCID mice 60 ASTEROID 60 ECASS 60 INSPIRE Trial Phase III 60 nonsmall cell lung cancer 60 observer blinded randomized 60 XOMA 3AB 60 nonclinical studies 60 DLTs 60 RECORD1 60 generation NNRTI 60 clevidipine 60 Nuvion 60 Combination REOLYSIN R 60 AVERROES 60 Amigal 60 CCR5 mAb 60 SNT MC# 60 GW# [003] 60 ozarelix 60 sapacitabine 60 TPI ASM8 60 multicentre phase 60 tremelimumab 60 Elagolix 60 BLA filing 60 Solorel TM 60 decitabine 60 visilizumab 60 afamelanotide 60 Insegia 60 Actemra tocilizumab 60 brivanib 60 TAXUS VI 60 Val HeFT 60 TEMODAL 60 Zenvia Phase III 60 ara C 60 Commences Phase 60 subcutaneous formulation 60 oral picoplatin 60 AZILECT ® 60 opioid induced bowel dysfunction 60 Dapagliflozin 60 Neo Bladder Augment 60 refractory multiple myeloma 59 sargramostim 59 Darusentan 59 Prospective Randomized 59 resminostat 59 Rebif ® 59 pan HDAC inhibitor 59 dyskinesia PD LID 59 Firazyr 59 AIR CF2 59 ADAGIO study 59 Prodarsan ® 59 APEX AMI trial 59 ON #.Na 59 tramiprosate ALZHEMED TM 59 dosage regimens 59 relapsed MCL 59 tezampanel NGX# 59 safety tolerability 59 CD# monoclonal antibody 59 Trovax 59 EOquin TM phase 59 EVEREST II 59 OvaRex R 59 micafungin 59 bazedoxifene 59 GSK# [002] 59 metastatic RCC 59 cinacalcet 59 Synavive 59 #I TM# 59 LY# [002] 59 RhuDex TM 59 NEVO ™ 59 TH# [003] 59 photoprotective drug 59 dose regimens 59 T DM1 59 Pertuzumab 59 histone deacetylase HDAC inhibitor 59 carboplatin paclitaxel 59 Azedra TM 59 Phase III Clinical Trial 59 receptor inhibitor 59 Ocrelizumab 59 AIR2 Trial 59 DXL# 59 IND enabling